Postma D S, Renkema T E, Koëter G H
Department of Pulmonology, University Hospital, Groningen, The Netherlands.
Agents Actions Suppl. 1990;30:41-57.
In order to improve our knowledge concerning the supposedly beneficial effects of corticosteroids in patients with "chronic bronchitis" and "chronic obstructive airway disease" (COAD), it is necessary to define our patients carefully, so that every investigator can interpret the data adequately. Up to now, no definite conclusion can be drawn as to the profitable effect of corticosteroids in COAD. A combination of data from many studies on oral and inhaled corticosteroids strongly suggests that long-term studies in large groups of patients are essential if we wish to determine a potential treatment effect. In this way, a sub-group of patients who improve on corticosteroids may be found too. In addition to objective measurements, e.g. degree of airflow obstruction and airway hyperresponsiveness (AH), subjective data and information on the patient's quality of life and exacerbations should be included for evaluation.
为了增进我们对皮质类固醇在“慢性支气管炎”和“慢性阻塞性气道疾病”(COAD)患者中假定的有益作用的了解,有必要仔细界定我们的患者群体,以便每位研究者都能充分解读数据。到目前为止,关于皮质类固醇在COAD中的有益效果尚无明确结论。来自多项关于口服和吸入皮质类固醇研究的数据综合起来有力地表明,如果我们想确定潜在的治疗效果,对大量患者进行长期研究至关重要。通过这种方式,或许还能找到在皮质类固醇治疗下病情改善的亚组患者。除了客观测量指标,如气流阻塞程度和气道高反应性(AH)外,还应纳入主观数据以及关于患者生活质量和病情加重情况的信息进行评估。